SPADE Clinical Trial.
NCT07892183
Summary
Purpose: This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical outcomes of the SPADE operation (Spade-Shaped Anastomosis) in patients undergoing laparoscopic or robotic proximal gastrectomy for early gastric cancer located in the upper stomach . Background: While proximal gastrectomy (removing only the upper part of the stomach) offers nutritional advantages over total gastrectomy, it often leads to significant postoperative reflux esophagitis * The SPADE technique was developed to prevent this by creating an artificial anti-reflux mechanism (angle of His and pseudo-fornix) using double suture anchoring between the esophagus and the stomach Study Plan: Participants: The study will enroll approximately 159 patients with tumors (size ≤ 4 cm) located in the upper third of the stomach who are eligible for gastric function-preserving surgery . Intervention: All participants will undergo laparoscopic or robotic proximal gastrectomy followed by the SPADE reconstruction method . Primary Objective: The primary goal is to determine the incidence of endoscopic reflux esophagitis at one year postoperatively . Secondary Objectives: Investigators will also monitor postoperative reflux symptoms, nutritional parameters (such as weight, hemoglobin, and vitamin B12 levels), surgical complications, quality of life, and 3-year survival rates . Hypothesis: The researchers hypothesize that the SPADE operation is a safe and effective surgical approach that can provide equivalent reflux prevention (a target rate of approximately 2.9%) compared to existing complex reconstruction methods, while maintaining the benefits of preserving gastric function
Eligibility
* Inclusion Criteria
① Histologically confirmed diagnosis of gastric adenocarcinoma by biopsy.
* Adult patients aged 20 years or older.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
④ American Society of Anesthesiologists (ASA) physical status classification of class I to III.
⑤ Patients who have received a full explanation of the study purpose and procedures, and voluntarily signed the informed consent form approved by the Institutional Review Board.
⑥ Patients eligible for proximal gastrectomy satisfying the following oncologic characteristics on preoperative evaluation:
• Tumor location: Upper third of the stomach (High body, cardia, fundus, gastroesophageal junction \[Siewert III\])
* Tumor size: 4 cm or less
* Preoperative clinical stage: T1N0, T1N1, T2N0, T2N1 (any differentiation)
* Preoperative clinical stage: T3N0, T3N1 (well or moderate differentiation)
* Expected residual stomach: 60% or more after surgery
* Exclusion Criteria
* Patients for whom total gastrectomy is the only appropriate treatment (e.g., presence of additional gastric cancer lesions in the distal stomach).
② Patients requiring concomitant resection of other organs due to other diseases.
③ Patients with other malignancies that may affect gastric function preservation indicators:
• History of cancer in other organs.
* Presence of concurrent cancer in other organs.
* History of previous gastric resection surgery. ④ Vulnerable populations: patients lacking decision-making capacity, pregnant women, or those planning pregnancy.Conditions9
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07892183